The development of clinically functional chimeric antigen receptor (CAR) T cell therapy is the
culmination of multiple advances over the last three decades. Axicabtagene ciloleucel …

Patients with follicular lymphoma (FL) frequently require multiple treatments during their
disease course; however, survival based on lines of treatment remains poorly described in …

Purpose Although the life expectancy of patients with follicular lymphoma (FL) has
increased, little is known of their causes of death (CODs) in the rituximab era. Patients and …

Duodenal‐type follicular lymphoma (DFL) is a newly recognised variant of follicular
lymphoma (FL), although little is known about its biology and clinical evolution. In general …

The use of immunochemotherapy has improved the outcome of follicular lymphoma (FL).
Recently, complete response at 30 months (CR 30) has been suggested as a surrogate for …

PURPOSE Real-world evidence on non-Hodgkin lymphoma (NHL) management in Latin
America is currently lacking. The objective of this study was to describe treatment …

Mantle cell lymphoma (MCL) is a rare form of non-Hodgkin's lymphoma (NHL) with a median
overall survival (OS) of approximately 3–5 years. Systematic literature reviews (SLRs) …

Introduction Follicular lymphoma (FL) is an indolent non-Hodgkin lymphoma that shows a
progressive increase in relapses and refractory in its natural history and a median survival of …

Abstract Deregulated phosphatidylinositide 3-kinase (PI3K) signaling plays a crucial role in
the biology of different lymphoma entities leading to the proliferation and survival of the …

Randomized trials of maintenance therapy (MT) in diffuse large B cell lymphoma (DLBCL)
are inconclusive regarding its effect on overall survival (OS) and disease control. We aimed …